Boardroom Alpha
Boardroom Alpha
CARL · Additional Proxy Materials (DEFA14A) · Filed April 22, 2026

Carlsmed Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 22, 2026
Ticker
CARL
Accession
0001794546-26-000006
Boardroom Alpha · Filing insights

Carlsmed recommends voting for Niall Casey and Philip Young and ratifying Ernst & Young as auditor.

About Carlsmed Inc
Market cap
$277M
Board grade
C-
Sector
Healthcare
CEO
Michael Cordonnier
Last annual meeting: Jun 3, 2026 · View full Carlsmed Inc profile →
DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

 

Preliminary Proxy Statement

 

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

 

Definitive Proxy Statement

 

 

Definitive Additional Materials

 

 

Soliciting Material under §240.14a-12

 

Carlsmed, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 

No fee required.

 

 

Fee paid previously with preliminary materials.

 

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 


 

 

img54671120_0.jpg

Your Vote Counts! CARLSMED, INC. 2026 Annual Meeting Vote by June 2, 2026 11:59 PM ET CARLSMED, INC. 1800 ASTON AVENUE, SUITE 100 CARLSBAD, CA 92008 ATTN: CORPORATE SECRETARY V91113-P44852 You invested in CARLSMED, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 3, 2026. Get informed before you vote We encourage you to access and review the proxy materials before voting. View the Notice of Annual Meeting of Stockholders, Proxy Statement and Annual Report on Form 10-K online at www.ProxyVote.com OR you can receive a free paper or email copy of the material(s) by requesting prior to May 20, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote in Person at the Meeting* June 3, 2026 8:00 A.M. Pacific Time The Offices of Morrison & Foerster LLP 12531 High Bluff Drive Suite 200 San Diego, CA 92130 *Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

 


 

 

img54671120_1.jpg

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming 2026 Annual Meeting of Stockholders. Please follow the instructions on the reverse side to vote these important matters. Voting Items Board Recommends 1. To elect two directors to serve as Class I directors for a three-year term to expire at the 2029 annual meeting of stockholders Nominees: 01) Niall Casey 02) Philip Young For 2. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 For NOTE: Such other business as may properly come before the meeting or any adjournment thereof will be voted on by the proxy holders in their discretion. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V91114-P44852.

 


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Carlsmed Inc (CARL)

Reference

Frequently asked questions

When did Carlsmed Inc file this DEFA14A?
Carlsmed Inc (CARL) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 22, 2026. The accession number assigned by EDGAR is 0001794546-26-000006.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Carlsmed recommends voting for Niall Casey and Philip Young and ratifying Ernst & Young as auditor. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Carlsmed Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Carlsmed Inc has filed under CIK 1794546, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer